Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
US Department of Justice
UBS
Queensland Health
Fish and Richardson
Colorcon
Johnson and Johnson
Boehringer Ingelheim
Healthtrust
US Army

Generated: January 19, 2018

DrugPatentWatch Database Preview

Astrazeneca Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for ASTRAZENECA PHARMS, and when can generic versions of ASTRAZENECA PHARMS drugs launch?

ASTRAZENECA PHARMS has twenty-four approved drugs.

There are seventy-two US patents protecting ASTRAZENECA PHARMS drugs and there have been three Paragraph IV challenges on ASTRAZENECA PHARMS drugs in the past three years.

There are one thousand four hundred and fifty-five patent family members on ASTRAZENECA PHARMS drugs in seventy-three countries and one hundred and three supplementary protection certificates in sixteen countries.

Summary for Astrazeneca Pharms
International Patents:1455
US Patents:72
Tradenames:21
Ingredients:18
NDAs:24

Drugs and US Patents for Astrazeneca Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms NEXIUM esomeprazole magnesium FOR SUSPENSION, DELAYED RELEASE;ORAL 022101-001 Feb 27, 2008 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms EPANOVA omega-3-carboxylic acids CAPSULE;ORAL 205060-001 May 5, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca Pharms ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Astrazeneca Pharms NEXIUM esomeprazole magnesium CAPSULE, DELAYED REL PELLETS;ORAL 021153-002 Feb 20, 2001 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca Pharms NEXIUM esomeprazole magnesium CAPSULE, DELAYED REL PELLETS;ORAL 021153-001 Feb 20, 2001 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca Pharms DALIRESP roflumilast TABLET;ORAL 022522-001 Feb 28, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca Pharms PRILOSEC omeprazole CAPSULE, DELAYED REL PELLETS;ORAL 019810-003 Oct 5, 1995 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca Pharms MOVANTIK naloxegol oxalate TABLET;ORAL 204760-002 Sep 16, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca Pharms BEVESPI AEROSPHERE formoterol fumarate; glycopyrrolate AEROSOL, METERED;INHALATION 208294-001 Apr 25, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca Pharms ALVESCO ciclesonide AEROSOL, METERED;INHALATION 021658-002 Jan 10, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Astrazeneca Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca Pharms NEXIUM esomeprazole magnesium FOR SUSPENSION, DELAYED RELEASE;ORAL 021957-001 Oct 20, 2006 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms NEXIUM esomeprazole magnesium CAPSULE, DELAYED REL PELLETS;ORAL 021153-002 Feb 20, 2001 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms PRILOSEC OTC omeprazole magnesium TABLET, DELAYED RELEASE;ORAL 021229-001 Jun 20, 2003 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms NEXIUM esomeprazole magnesium FOR SUSPENSION, DELAYED RELEASE;ORAL 021957-002 Oct 20, 2006 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms SEROQUEL quetiapine fumarate TABLET;ORAL 020639-002 Sep 26, 1997 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms NEXIUM esomeprazole magnesium CAPSULE, DELAYED REL PELLETS;ORAL 021153-002 Feb 20, 2001 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms NEXIUM esomeprazole magnesium FOR SUSPENSION, DELAYED RELEASE;ORAL 021957-002 Oct 20, 2006 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms CASODEX bicalutamide TABLET;ORAL 020498-001 Oct 4, 1995 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms PRILOSEC omeprazole CAPSULE, DELAYED REL PELLETS;ORAL 019810-003 Oct 5, 1995 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ASTRAZENECA PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 60 mg ➤ Subscribe 9/30/2015
➤ Subscribe Tablets 90 mg ➤ Subscribe 7/20/2015
➤ Subscribe Tablets 500 mcg ➤ Subscribe 3/2/2015
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 3/30/2012
➤ Subscribe Nasal Spray 250 mcg ➤ Subscribe 2/13/2012
➤ Subscribe Inhalation Suspension 1 mg/2 mL ➤ Subscribe 5/28/2010
➤ Subscribe For Injection 20 mg/vial and 40 mg/vial ➤ Subscribe 11/23/2009
➤ Subscribe Delayed-release Capsules 20 mg ➤ Subscribe 3/19/2007
➤ Subscribe Tablets 50 mg, 150 mg and 400 mg ➤ Subscribe 2/12/2007
➤ Subscribe Tablets 100 mg, 200 mg and 300 mg ➤ Subscribe 2/21/2006
➤ Subscribe Inhalation Suspension 0.25 mg/2 mL and 0.5 mg/2 mL ➤ Subscribe 9/15/2005
➤ Subscribe Tablets 25 mg ➤ Subscribe 8/12/2005
➤ Subscribe Delayed-release 20 mg and 40 mg ➤ Subscribe 8/5/2005

Non-Orange Book US Patents for Astrazeneca Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,745,466 Form of S-omeprazole ➤ Subscribe
7,196,098 Quinuclidine derivatives and medicinal compositions containing the same ➤ Subscribe
9,687,478 Quinuclidine derivatives and medicinal compositions containing the same ➤ Subscribe
5,290,539 Device for delivering an aerosol ➤ Subscribe
7,750,006 Phthalazinone derivatives ➤ Subscribe
8,349,307 Polymer conjugates of opioid antagonists ➤ Subscribe
7,692,006 Phthalazinone derivatives ➤ Subscribe
7,897,617 Quinuclidine derivatives and medicinal compositions containing the same ➤ Subscribe
7,750,023 Quinuclidine derivatives and medicinal compositions containing the same ➤ Subscribe
7,214,687 Quinuclidine derivatives and medicinal compositions containing the same ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Astrazeneca Pharms Drugs

Supplementary Protection Certificates for Astrazeneca Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00737 Netherlands ➤ Subscribe PRODUCT NAME: NALOXEGOL ALSMEDE DOOR HET BASISOCTROOI; REGISTRATION NO/DATE: EU/1/14/962 20141208
C0016 France ➤ Subscribe PRODUCT NAME: TICAGRELOR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/10/655/001 DU 20101203; REGISTRATION NO/DATE AT EEC: EU/1/10/655/001-006 DU 20101203
00726 Netherlands ➤ Subscribe PRODUCT NAME: OLAPARIB, EN ZOUTEN EN; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
C/GB09/059 United Kingdom ➤ Subscribe PRODUCT NAME: GEFITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 56154 20040302; UK EU/1/09/526/001 20090624
631 Luxembourg ➤ Subscribe 91631, EXPIRES: 20210423
C022/2005 Ireland ➤ Subscribe SPC022/2005, 20060612, EXPIRES: 20190415
2013 00002 Denmark ➤ Subscribe
C/GB01/006 United Kingdom ➤ Subscribe PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
2011005,C0984957 Lithuania ➤ Subscribe PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
2012000051 Germany ➤ Subscribe PRODUCT NAME: KOMBINATIONSPRODUKT UMFASSEND NAPROXEN UND ESOMEPRAZOL-MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Moodys
Harvard Business School
Cerilliant
Julphar
Johnson and Johnson
Cipla
Argus Health
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot